Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Robert J. Rodriguez"'
Autor:
Claudia Maturo, Zuzana Zachar, James F. Marecek, Robert Shorr, Joanna Lem, Sameer Karnik, Paul M. Bingham, Sunita Gupta, Shawn D. Stuart, Robert J. Rodriguez, Alexandra Schauble, Katy Howell, Arin Piramzadian, King Lee
Publikováno v:
Journal of Molecular Medicine. 89:1137-1148
We report the analysis of CPI-613, the first member of a large set of analogs of lipoic acid (lipoate) we have investigated as potential anticancer agents. CPI-613 strongly disrupts mitochondrial metabolism, with selectivity for tumor cells in cultur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54f4b2975b6c03fe6a8dafe37ce1655a
https://doi.org/10.1007/s00109-011-0785-8
https://doi.org/10.1007/s00109-011-0785-8
Publikováno v:
Organic Process Research & Development. 15:855-857
An efficient and practical synthesis of the novel anti-tumor compound 6,8-dithiobenzyl octanoic acid, CPI-613 (2), was developed and executed on a practical scale. CPI-613 can be made in a single vessel from (±)-lipoic acid (1) via reductive opening
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b730437313cd3588fba7eddcab5ee595
https://doi.org/10.1021/op200091t
https://doi.org/10.1021/op200091t
Autor:
King Chung Lee, Timothy S. Pardee, John Luddy, Sarah Dralle, Robin Harrelson, David D. Hurd, Leslie R. Ellis, Bayard L. Powell, Robert J. Rodriguez, Kristin Stadelman, Claudia Maturo, Megan Manuel, Denise Levitan, Scott Isom, Susan Lyerly, Lance D. Miller
Purpose: The lipoate derivative CPI-613 is a first-in-class agent that targets mitochondrial metabolism. This study determined the effects of CPI-613 on mitochondrial function and defined the MTD, pharmacokinetics, and safety in patients with relapse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4edebe2b2d0164b35200c499fddb33f
https://europepmc.org/articles/PMC4199870/
https://europepmc.org/articles/PMC4199870/
Publikováno v:
Journal of nanoscience and nanotechnology. 11(8)
Paclitaxel is an important anticancer drug and is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma. The objectives of the studies were to assess a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbe3cd572bb99f3a913c471305820d54
https://pubmed.ncbi.nlm.nih.gov/22103064
https://pubmed.ncbi.nlm.nih.gov/22103064
Autor:
Lakmal W. Boteju, Robert J. Rodriguez, King Chung Lee, Robert Shorr, Adrian Sheldon, Claudia Maturo
Publikováno v:
Drug metabolism letters. 5(3)
CPI-613 is a novel anti-tumor compound with a mechanism-of-action which appears distinct from the current classes of anti-cancer agents used in the clinic. CPI-613 demonstrates both in vitro and in vivo anti-tumor activity. In vitro metabolic studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::078952a6f0030f47eac775d9900778cb
https://pubmed.ncbi.nlm.nih.gov/21722089
https://pubmed.ncbi.nlm.nih.gov/21722089
Autor:
Paul J. Shrimpton, Rudolf Konrad Allemann, Richard S. Swanwick, Jiayun Pang, Giovanni Maglia, Robert J. Rodriguez, Rhiannon M. Evans, Lai-Hock Tey
Publikováno v:
Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 361(1472)
Dihydrofolate reductase (DHFR) maintains the intracellular pool of tetrahydrofolate through catalysis of hydrogen transfer from reduced nicotinamide adenine dinucleotide to 7,8-dihydrofolate. We report results for pre-steady-state kinetic studies of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29dd90d5fbf10cb50ce229222d9e32b1
https://pubmed.ncbi.nlm.nih.gov/16873119
https://pubmed.ncbi.nlm.nih.gov/16873119
Autor:
Robert J. Rodriguez, Timothy S. Pardee, John Luddy, Susan Lyerly, Claudia Maturo, Scott Isom, David D. Hurd, Denise Levitan, Bayard L. Powell, Megan Manuel, Robin Harrelson, Leslie R. Ellis, Sarah Dralle, King Chung Lee
Publikováno v:
Blood. 122:486-486
Background Altered metabolism is a hallmark of cancer, including hematologic malignancies. Cancer cells alter the normally catabolic role of their mitochondria to produce biosynthetic precursors to more efficiently generate additional cancer cells. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec4c27aefa307cd9fb6e64638395ae12
https://doi.org/10.1182/blood.v122.21.486.486
https://doi.org/10.1182/blood.v122.21.486.486